S100A8 and Ventricular arrhythmia: revealed that S100A8/A9 levels were lower in patients with HF, implantable cardioverter defibrillator, and sustained ventricular arrhythmias during a four-year follow-up period, suggesting the potential role of S100A8/A9 as a prognostic biomarker of sudden cardiac death in this population (68).